RT Journal Article
SR Electronic
T1 Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.26.21261130
DO 10.1101/2021.07.26.21261130
A1 Mie Agermose Gram
A1 Jens Nielsen
A1 Astrid Blicher Schelde
A1 Katrine Finderup Nielsen
A1 Ida Rask Moustsen-Helms
A1 Anne Katrine Bjørkholt Sørensen
A1 Palle Valentiner-Branth
A1 Hanne-Dorthe Emborg
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.07.26.21261130.abstract
AB Background The recommendations in several countries to stop using the ChAdOx1 vaccine has led to vaccine programs combining different vaccine types, which necessitates new knowledge on vaccine effectiveness (VE). In this study, we aimed to estimate the VE when combining the ChAdOx1 vaccine as the first dose and an mRNA vaccine as the second dose.Methods This nationwide population-based cohort study estimated VE against SARS-CoV-2 infection, all-cause and COVID-19 related hospitalization and death after receiving the ChAdOx1 vaccine as the first dose followed by an mRNA vaccine as the second dose. VE estimates were obtained using a Cox regression with calendar time as underlying time and adjusted for sex, age, comorbidity, heritage and hospital admission. Information on all individuals was extracted and linked from high-quality national registries.Results A total of 5,542,079 individuals were included in the analyses (97.6% of the total Danish population). A total of 144,360 were vaccinated with the ChAdOx1 vaccine as the first dose and of these 136,551 individuals received an mRNA vaccine as the second dose. A total of 1,691,464 person-years and 83,034 cases of SARS-CoV-2 infection were included. The VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88% (95% confidence interval (CI): 83; 92) 14 days after the second dose and onwards. There were no COVID-19 related hospitalizations and deaths among the individuals vaccinated with the combination of the ChAdOx1 and an mRNA vaccine during the study period.Conclusion In conclusion, this study found a reduction in the risk of SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine, compared with unvaccinated individuals. This is similar to the VE of two doses of an mRNA vaccine. Longer follow-up time is needed to confirm vaccine induced protection against severe events, such as COVID-19 related hospitalization and death.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data included in this research is part of the Danish national COVID-19 surveillance system database at Statens Serum Institut. The data are available for research upon reasonable request and with permission from the Danish Data Protection Agency and Danish Health and Medicines Authority. Ethics: We used only administrative register data for the study. According to Danish law, ethics approval is exempt for such research, and the Danish Data Protection Agency, which is a dedicated ethics and legal oversight body, thus waives ethical approval for our study of administrative register data, when no individual contact of participants is neccessary and only aggregate results are included as findings. The study is therefore fully compliant with all legal and ethical requirements and there are no further processes available regarding such studies.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBecause of data protection regulation, data cannot be shared directly by the authors. Data is accessible to researchers from an authorised institution after permission from the Danish Data Protection Agency and Danish Health and Medicines Authority